Tandem Diabetes Care Shares Gain 9.7% on FDA OK
Provided by
Dow Jones
By Ben Glickman
Shares of Tandem Diabetes Care climbed Tuesday after the company said the U.S. Food and Drug Administration cleared its Tandem Mobi insulin pump.
The stock was up 9.7% to $27.35 in mid-morning trading. Shares are down 39% year to date.
The San Diego-based diabetes technology company said its miniature insulin pump had received clearance for people with diabetes age 6 and older, and was the world's smallest durable insulin-delivery system.
Tandem said it expects a limited release of the Tandem Mobi in late 2023 and a full commercial release by early 2024.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
July 11, 2023 10:46 ET (14:46 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What Does Nvidia’s Stock Split Mean for Investors?
-
After Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Baidu Stock a Buy, a Sell, or Fairly Valued?
-
Why Stocks Are Hitting Record Highs—and What Could Send Them Back to Earth
-
5 Stocks to Buy While They’re Trading at Big Discounts
-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
After Earnings, Is Applied Materials Stock a Buy, Sell, or Fairly Valued?
-
The Best Energy Stocks to Buy
-
Snowflake Earnings: Mixed News, But Signs of Stability
-
Nvidia Earnings: AI Demand Smashes Expectations Again
-
After Earnings, Is Walmart Stock a Buy, a Sell, or Fairly Valued?
-
Target Earnings: Margins Hold Up, but Top Line Constrained by Weak Discretionary Spending
-
Is Berkshire Hathaway’s Mystery Stock a Buy?
-
After Earnings, Is Uber Stock a Buy, a Sell, or Fairly Valued?